Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $15.60.

KLRS has been the subject of a number of recent research reports. TD Cowen initiated coverage on Kalaris Therapeutics in a research note on Monday. They issued a “buy” rating for the company. Morgan Stanley initiated coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 target price for the company. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th. Wedbush began coverage on Kalaris Therapeutics in a research note on Thursday, May 14th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday.

Insider Activity

In other Kalaris Therapeutics news, Director Srinivas Akkaraju acquired 244,300 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $4.83 per share, with a total value of $1,179,969.00. Following the transaction, the director owned 2,224,147 shares of the company’s stock, valued at $10,742,630.01. This trade represents a 12.34% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 68.10% of the company’s stock.

Institutional Trading of Kalaris Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp increased its position in shares of Kalaris Therapeutics by 12.4% during the 4th quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after purchasing an additional 2,800 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $34,000. Barclays PLC acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $51,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth about $58,000. Finally, Keel Point LLC acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter worth about $86,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Stock Down 1.4%

Shares of KLRS opened at $4.27 on Tuesday. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $11.88. The company has a market capitalization of $101.58 million, a PE ratio of -1.99 and a beta of 0.15. The stock has a fifty day simple moving average of $5.32 and a two-hundred day simple moving average of $7.41.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. As a group, equities analysts anticipate that Kalaris Therapeutics will post -2.09 earnings per share for the current fiscal year.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.